SCHEMBL15907308

SCHEMBL15907308

COc1cn2c(C#Cc3cccc(C(=O)Nc4cncnc4OC)c3)nnc2cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.38
KIT P10721 2/20 0.38
DDR1 Q08345 2/20 0.38
MAPK1 P28482 1/20 0.36
GRM5 P41594 6/20 0.35
EGFR P00533 1/20 0.35
LCK P06239 2/20 0.35
TEK Q02763 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
HAO1 Q9UJM8 1/20 0.35
MAPT P10636 1/20 0.34
POLB P06746 1/20 0.34
TSHR P16473 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KEAP1 Q14145 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15907315 0.88 KIT (0.39) CSF1RKITDDR1GRM5EGFR
SCHEMBL15907240 0.87 NPC1 (0.42) CSF1RKITDDR1GRM5EGFR
SCHEMBL15907282 0.81 CHEK1 (0.38) CSF1RKITDDR1MAPK1EGFR
SCHEMBL18323185 0.78 GRM5 (0.41) CSF1RKITDDR1GRM5LCK
SCHEMBL15907307 0.77 CSF1R (0.40) CSF1RKITDDR1GRM5LCK
SCHEMBL15907191 0.77 EGFR (0.43) GRM5EGFRMEN1KMT2APOLB
SCHEMBL15907268 0.74 CSF1R (0.37) CSF1RKITDDR1GRM5
SCHEMBL15907306 0.74 KMT2A (0.41) CSF1RKITDDR1MAPK1MEN1
SCHEMBL18323146 0.73 GRM5 (0.37) CSF1RKITDDR1GRM5TSHR
SCHEMBL15907285 0.71 GPR6 (0.36) DDR1TEKMEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon ABL1, ABL2, MAP3K6 CSF1R 1848/4885KIT 577/4885DDR1 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.